Kura Oncology (NASDAQ:KURA) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA) from a sell rating to a hold rating in a report released on Thursday.

A number of other brokerages also recently issued reports on KURA. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Thursday. JMP Securities restated a “market outperform” rating and set a $28.00 price target on shares of Kura Oncology in a research report on Thursday, February 6th. Jefferies Financial Group lowered their price objective on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. Finally, Scotiabank reduced their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Trading Down 1.5 %

Shares of KURA stock opened at $7.65 on Thursday. The stock has a market capitalization of $594.89 million, a price-to-earnings ratio of -3.24 and a beta of 0.78. The company’s fifty day simple moving average is $8.19 and its two-hundred day simple moving average is $13.92. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. As a group, analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock valued at $92,307 over the last ninety days. 5.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently modified their holdings of KURA. Virtus ETF Advisers LLC boosted its holdings in Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after acquiring an additional 3,061 shares during the period. Point72 DIFC Ltd bought a new stake in Kura Oncology during the third quarter valued at about $146,000. Harbor Advisors LLC purchased a new position in shares of Kura Oncology in the 4th quarter worth approximately $87,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology in the fourth quarter worth $90,000. Finally, Erste Asset Management GmbH purchased a new position in Kura Oncology during the 3rd quarter worth $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.